References
- Kaplan L. M., Hollander D. Respiratory dysfunction in amyotrophic lateral sclerosis. Clin Chest Med 1994; 15: 675–81
- Lyall R. A., Donaldson N., Polkey M. I., Leigh P. N., Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001; 124: 2000–13
- Fitting J. W., Paillex R., Hirt L., Aebischer P., Schluep M. Sniff nasal pressure: a sensitive respiratory test to assess progression of ALS. Ann Neurol 1999; 46: 887–93
- Mendoza M., Moore D., Gelinas D., Miller R. A. Comparison of MIP and FVC in ALS. Eleventh Annual Symposium on ALS/NMD Dec. 2000; 1((Suppl 3))39
- Miller R. G., Rosenberg J. A., Gelinas D. F., Mitsumoto H., Newman D., Sufit R., et al. Practice parameter: the care of the patient with ALS (an evidence based review). Report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology 1999; 52: 1311–23
- Miller R. G., Moore D. H., Gelinas D. F., Dronsky V., Mendoza M., Barohn R. J., et al. Phase III randomised trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56: 843–8
- The BDNF study group. A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 1999; 52: 1427–33
- Griggs R. C. The use of pulmonary function testing as a quantitative measurement for therapeutic trials. Muscle Nerve 1990; 13((suppl))S30–4
- Stembler N., Charatan M., Cederbaum J. M., the ALS CTNF Treatment Study Group. Prognostic indicators of survival in ALS. Neurology 1998; 50: 66–72
- Bradley W. G., Miller R. G., the BDNF Study Group. Phase III trial of subcutaneous recombinant methionyl human BDNF in patients with ALS. Neurology 1999; 52: 1427–33
- American Thoracic Society. Standardization of spirometry (1987 update). Am Rev Respir Dis 1987; 136: 1285–96
- American Thoracic Society Statement. Standardization of spirometry (1994 update). Am J Resp Crit Care Med 1994; 152: 1107–36
- Bland J. M., Altman D. G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 8: 307–10
- Fritzgerald M. X., Smith A. A., Garnsler E. A. Evaluation of ‘electronic’ spirometers. N Engl J. Med 1973; 289: 1283–6
- Gardner R. M., Hankinson J. L., West B. J. Evaluating commercially available spirometers. Am Rev Respir Dis 1980; 121: 73–82
- Nelson S. B., Gardner R. M., Crapo R. O., Jensen R. L., et al. Performance evaluation of contemporary spirometers. Chest 1990; 97: 288–97
- Hayot M., Reneaux C., Barabe P., Préfaut C., et al. Les spiromètres portables, gadgets peu fiables ou véritables outils professionnels? Un essai comparatif pour guider vos choix. Bulletin Soc de Pneumologie de Langue Française. 1996; 4
- Quanjer P. H., Tammeling G. J., Cotes O. F., Pedersen O. F., Peslin R., Yemault J. C., et al. Lung volumes and forced ventilatory flows. Report of working party. Standardisation of lung function tests, European community for steel and coal. Eur Resp J 1993; 6((Suppl 16))5–40
- Sanjak M., Salachas P., Frija‐Orvoen F., Theys P., Hutchinson D., Verheijde J., et al. Prospective quality control of VC as primary end point in international multicentre therapeutic trial of xaliproden in ALS. Eleventh Annual Symposium on ALS/NMD, Dec. 2000;. ALS 2000; 1(Suppl 3)59–60
- Polkey M. I., Lyall R. A., Moxham J., Leigh P. N., et al. Respiratory aspects of neurological disease. J Neurol Neurosurg Psychiatry 1999; 66: 5–15
- Fallat R. J., Jewitt B., Bass M., Kamm B., Norris F. Spirometry in ALS. Arch Neurol 1979; 36: 74–80
- Shiffman P. L., Belch J. M. Pulmonary function at diagnosis of amyotrophic lateral sclerosis: rate of deterioration. Chest 1993; 103: 508–13
- Enright P. L., Hyatt R. E. Office spirometry. A practical guide to the selection and use of spirometers. Lea and Febiger Edit., Philadelphia. 1987; 253
- Gardner R. M., Clausen J. L., Epler G., Hankinson J. L., Permutt S., Plummer A. L., et al. Pulmonary function laboratory personnel qualifications. Am Rev Respir Dis 1986; 134: 6232–624